| Developers: | Revance Therapeutics |
| Date of the premiere of the system: | September 2022 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
2022: Drug Market Launch
On September 8, 2022, the biotech company Revance Therapeutics released a drug to combat wrinkles. The drug could be the first competitor to disrupt Botox's dominance in AbbVie the market.
A new drug called Daxxify (daxibotulinumtoxinA) is used in cosmetic procedures to temporarily eliminate moderate to severe glabellar (frown) wrinkles. Like Botox, Daxxify is an injectable neuromodulator. But Revance's product is the first based on peptide exchange technology.
The key difference between Daxxify is its duration of action. While Botox injections last for three months, Daxxify can last for six months and in some patients up to nine months. The duration-of-action benefits of Daxxify were established in Phase 3 trials involving 2,700 patients and 4,200 procedures. Studies have shown that one injection has a powerful effect on wrinkles.
 | Daxxify sets a new standard in neuromodulator formulation development, Revance CEO Mark Foley said during a call with investors. The neuromodulator market has remained virtually unchanged for more than 30 years and is ripe for innovation. Although new products have appeared on the market, they all have similar formulas and efficacy profiles, providing an average duration of effect of 12 to 16 weeks. |  |
The most unmet need to use toxins is the duration of action, Foley said. We have a fantastic characteristic. We worked very closely with the FDA to include all 36 weeks of data in the label, allowing us to support these marketing statements.
Revance is also investigating Daxxify for therapeutic benefits. It is planned to approve the drug for the treatment of cervical dystonia. Phase 2 study for labial spasticity completed.
The company has yet to announce the price of the drug Daxxify. Revance President Dustin Suites said the company will gradually bring the drug to market, starting with a pre-launch program for some physicians and then moving to a broader commercial launch in 2023.[1][2]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |